Category: biotech

.Achilles Rehabs has actually shreded its own approach. The English biotech is actually quiting working on its own clinical-phase cell therapy, considering handle teams working

.Phone it an instance of really good chemistry: Acepodia, a biotech based upon Nobel Prize-winning scientific research, is actually taking part in a brand new

.Despite izokibep preserving its newfound winning streak in the center, Acelyrin is actually no more focusing on its former lead resource as component of a

.Invite to this week’s Chutes &amp Ladders, our summary of considerable management hirings, shootings and also retirings across the industry. Feel free to send out

.Simply a handful of brief full weeks after winning an FDA Fast lane tag for its investigational BTK degrader in particular blood cancers, BeiGene has

.AbbVie has actually come back to the resource of its antipsychotic goliath Vraylar looking for another smash hit, paying for $25 thousand in advance to

.On the same time that some Parkinson’s ailment drugs are actually being actually disputed, AbbVie has actually revealed that its late-stage monotherapy candidate has actually

.Within this full week’s episode of “The Best Line,” our team’re diving into Strong Biotech’s annual Brutal 15 unique record. Brutal Biotech’s Annalee Armstrong as

.Monopar Therapeutics is recouping a medication coming from the scrap heap of AstraZeneca’s rare ailment pipeline. It has licensed ALXN-1840, a prospect for the treatment

.AstraZeneca has actually used expert system to develop an one-of-a-kind biomarker for its Daiichi Sankyo-partnered datopotamab deruxtecan (Dato-DXd), intending to vary the antibody-drug conjugate (ADC)